FRNT Financial Inc. Announces $3.0M Brokered Financing
FRNT Financial Inc. Announces $3.0M Brokered Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
不用于分发给美国新闻通讯社或在美国传播
TORONTO, April 05, 2024 (GLOBE NEWSWIRE) -- FRNT Financial Inc. (TSXV:FRNT) (OTCQB:FRFLF) (FSE:XZ3) (the "Company" or "FRNT") is pleased to announce a brokered private placement offering of up to 5,000,000 units of the Company ("Units") at a price of C$0.60 per Unit (the "Offering Price"), for aggregate gross proceeds of up to C$3,000,000 (the "LIFE Offering"). The Offering is being led by Fort Capital Securities Ltd. (the "Agent") as the sole agent and sole bookrunner on a "best efforts" basis.
多伦多,2024年4月5日(环球通讯社)——FRNT Financial Inc.(多伦多证券交易所股票代码:FRNT)(OTCQB: FRFLF)(FSE: XZ3)(“公司” 或 “FRNT”)欣然宣布以每单位0.60加元的价格进行公司高达500万个单位(“单位”)的经纪私募发行(“发行价格”)”),总收益不超过300万加元(“人寿发行”)。本次发行由Fort Capital Securities Ltd.(“代理人”)作为独家代理人和唯一账簿管理人在 “尽最大努力” 的基础上牵头。
Each Unit will be comprised of one common share of the Company (a "Common Share") and one-half of one Common Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share (each, a "Warrant Share") at an exercise price of C$0.90 for 36 months following the completion of the LIFE Offering, subject to accelerated expiry in the event the volume-weighted average closing price of the Common Shares on the TSX Venture Exchange (the "TSXV") is $1.20 or more for ten (10) consecutive trading days, in which case the Company may accelerate the expiry date of the Warrants to the date that is thirty (30) days following the issuance of a news release by the Company announcing such acceleration.
每个单位将由公司的一股普通股(“普通股”)和一半的普通股购买权证(每份完整认股权证,一份 “认股权证”)组成。每份认股权证的持有人将有权在LIFE发行完成后的36个月内以0.90加元的行使价购买一股普通股(每股 “认股权证”),但如果多伦多证券交易所风险交易所(“TSXV”)普通股的交易量加权平均收盘价在连续十(10)个交易日达到1.20美元或以上,在这种情况下,公司可能会加快到期认股权证的日期至公司发布新闻稿后的三十(30)天内宣布这样的加速。
The Units to be issued under the LIFE Offering will be offered to purchasers pursuant to the Listed Issuer Financing Exemption (the "LIFE Exemption") under Part 5A of National Instrument 45-106 – Prospectus Exemptions, in Alberta, British Columbia, Manitoba, Ontario and Saskatchewan. The Units offered will not be subject to a hold period in accordance with applicable Canadian securities laws.
根据National Instrument 45-106第5A部分的上市发行人融资豁免(“人寿豁免”),在人寿发行下发行的单位将提供给买方— 招股说明书豁免,位于艾伯塔省、不列颠哥伦比亚省、曼尼托巴省、安大略省和萨斯喀彻温省。根据适用的加拿大证券法,所提供的单位不受持有期限制。
There is an offering document (the "Offering Document") related to the LIFE Offering that can be accessed under the Company's profile on SEDAR+ at and on the Company's website at . Prospective investors of the Units should read the Offering Document before making an investment decision.
有一份与LIFE发行相关的发行文件(“发行文件”)可以在SEDAR+的公司简介下访问,网址为 并在公司的网站上 。在做出投资决定之前,该单位的潜在投资者应阅读发行文件。
The Company intends to use the net proceeds from the LIFE Offering to continue scaling its business and building out its capital base, and for working capital and general corporate purposes, as more specifically described in the Offering Document. The LIFE Offering is scheduled to close on or about April 30, 2024 or such other date that is within 45 days from April 5, 2024 as the Company and Agent may agree (the "Closing Date"). The Life Offering remains subject to certain conditions customary for transactions of this nature, including, but not limited to, the receipt of all necessary approvals, including the approval of the TSXV.
正如发行文件中更具体地描述的那样,公司打算将LIFE发行的净收益用于继续扩大业务规模和建立资本基础,并用于营运资金和一般公司用途。LIFE发行计划于2024年4月30日左右或自2024年4月5日起45天内的其他日期(“截止日期”)结束。人寿发行仍需遵守此类性质交易的某些惯用条件,包括但不限于获得所有必要的批准,包括多伦多证券交易所的批准。
The securities to be offered pursuant to the LIFE Offering, and sale of the Additional Units, have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
根据LIFE发行发行的证券以及额外单位的销售,过去和将来都不会根据经修订的1933年《美国证券法》(“美国证券法”)或任何美国州证券法进行注册,也不得在美国境内发行或出售,也不得向未经注册或未经美国注册要求的适用豁免的美国人发行或出售,或为其账户或利益进行发行或出售。《证券法》和适用的美国州证券法。本新闻稿不应构成在美国出售证券的要约或征求购买证券的要约,也不得在任何此类要约、招揽或出售非法的司法管辖区出售这些证券。
About FRNT
FRNT is an institutional capital markets and advisory platform focused on digital assets. FRNT, through a technology-forward and compliant operation, aims to bridge the worlds of traditional and web-based finance. Partnering with both financial institutions and crypto native firms, FRNT operates 5 synergistic business lines including deliverable trading services, institutional structured derivative products, merchant banking, advisory and consulting, and principal investments & trading. Co-founded in 2018 by CEO Stéphane Ouellette, FRNT is a global firm headquartered in Toronto, Canada.
关于 FRNT
FRNT是一个专注于数字资产的机构资本市场和咨询平台。FRNT通过技术前沿和合规的运营,旨在架起传统金融和网络金融世界的桥梁。FRNT与金融机构和加密原生公司合作,运营5条协同业务线,包括可交付交易服务、机构结构性衍生品产品、商业银行、咨询和咨询以及本金投资和交易。FRNT是一家全球性公司,总部位于加拿大多伦多,由首席执行官斯蒂芬·欧莱特于2018年共同创立。
FRNT Financial Inc.
Chief Executive Officer
Stéphane Ouellette
investors@frnt.io
833 222-3768
FRNT 金融公司
首席执行官
Ste'phane Ouellette
investors@frnt.io
833 222-3768
Neither the TSXV nor its regulation services provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.
多伦多证券交易所及其监管服务提供商(该术语在多伦多证券交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。
FORWARD-LOOKING STATEMENTS
前瞻性陈述
This press release contains "forward-looking statements" and "forward-looking information" within the meaning of applicable law which may include, without limitation, statements relating to the terms and completion of the LIFE Offering, the use of proceeds of the LIFE Offering, the receipt of TSXV approval in respect of the LIFE Offering, acceleration of the expiry date of the Warrants, the technical, financial and business prospects of the Company, its assets and other matters. Generally, forward-looking statements and forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". All forward-looking statements and forward-looking information are based on reasonable assumptions that have been made by the Company as at the date of such information. Forward-looking statements and forward-looking information are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements and forward-looking information, including but not limited to: the general risks associated with the speculative nature of the Company's business, current global financial conditions, uncertainty of additional capital, price volatility, no history of earnings, government regulation in the industries in which the Company operates, political and economic risk, absence of public trading market, arbitrary offering price, dilution to the Company's common shares, dependence on key personnel, currency fluctuations, insurance and uninsured risks, competition, legal proceedings, conflicts of interest and lack of dividends. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements and forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or forward-looking information. The Company does not undertake to update any forward-looking statement or forward-looking information that is included herein, except in accordance with applicable securities laws.
本新闻稿包含适用法律所指的 “前瞻性陈述” 和 “前瞻性信息”,其中可能包括但不限于与人寿发行的条款和完成情况、人寿发行收益的使用、多伦多证券交易所就人寿发行获得多伦多证券交易所批准、认股权证到期日期的加快、公司的技术、财务和业务前景、其资产和其他事项相关的陈述。通常,前瞻性陈述和前瞻性信息可以通过使用前瞻性术语来识别,例如 “计划”、“预期” 或 “不期望”、“预期”、“预算”、“估计”、“打算”、“预期” 或 “不预期”、“相信”,或某些行动、事件或结果 “可能”、“可能” 的措辞和短语或陈述的变体, “将”, “可能” 或 “将被采取”, “发生” 或 “实现”.所有前瞻性陈述和前瞻性信息均基于公司在发布此类信息之日做出的合理假设。前瞻性陈述和前瞻性信息受已知和未知风险、不确定性和其他因素的影响,这些因素可能导致公司的实际业绩、活动水平、业绩或成就与此类前瞻性陈述和前瞻性信息所表达或暗示的存在重大差异,包括但不限于:与公司业务投机性质相关的一般风险、当前的全球财务状况、额外资本的不确定性、价格波动、无历史记录收益、公司经营所在行业的政府监管、政治和经济风险、缺乏公开交易市场、任意发行价格、稀释公司普通股、对关键人员的依赖、货币波动、保险和未投保风险、竞争、法律诉讼、利益冲突和缺乏股息。尽管公司试图确定可能导致实际业绩与前瞻性陈述和前瞻性信息中包含的业绩存在重大差异的重要因素,但可能还有其他因素导致业绩与预期、估计或预期不符。无法保证此类信息会被证明是准确的,因为实际结果和未来事件可能与此类陈述或信息中的预期存在重大差异。因此,读者不应过分依赖前瞻性陈述或前瞻性信息。除非根据适用的证券法,否则公司不承诺更新此处包含的任何前瞻性陈述或前瞻性信息。
译文内容由第三方软件翻译。